Ask about this productRelated genes to: CD117 antibody
- Gene:
- KIT NIH gene
- Name:
- KIT proto-oncogene, receptor tyrosine kinase
- Previous symbol:
- PBT
- Synonyms:
- CD117, SCFR, C-Kit
- Chromosome:
- 4q12
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2019-04-23
Related products to: CD117 antibody
Related articles to: CD117 antibody
- This study aimed to explore whether CD74 participates in regulating ferroptosis and to clarify the related mechanisms in traumatic brain injury (TBI). - Source: PubMed
Sun GuangWeiLi JieWang MengLu KunLiu DanDanHu ChangLongQiu Tao - Neurotrophic tyrosine receptor kinase (NTRK) fusions are crucial in tumorigenesis and in guiding targeted therapy with TRK inhibitors. However, their rarity, fusion heterogeneity, and limitations of conventional pan-TRK immunohistochemistry (IHC) impede accurate clinical detection. This multicenter retrospective study analyzed 374 NGS/FISH-validated samples (195 NTRK - positive and 179 NTRK - negative) collected from 12 Chinese centers to investigate fusion heterogeneity and refine the interpretation of pan-TRK IHC. We developed an amplified protocol by combining the traditional pan-TRK IHC (EPR17341) with the OptiView Amplification kit and established new interpretation criteria. A total of 40 solid tumor types were included, and 23 unique fusion partners were identified. Papillary thyroid cancer was the most common NTRK-positive tumor (49.74 %) and harbored all three NTRK subtypes. Among NTRK-positive samples, NTRK3 (74.87 %) was the most prevalent subtype, followed by NTRK1 (23.59 %). ETS variant transcription factor 6 (ETV6) was the most frequent fusion partner, identified in 122 out of 195 cases. It was uniquely shared across all three NTRK subtypes, with its fusion to NTRK1 being reported for the first time. NTRK1 and NTRK3 exhibited marked fusion partner specificity, with no overlap in their associated partners except for ETV6. The optimized pan-TRK IHC protocol significantly improved staining efficiency by enhancing intensity and clarity. Consequently, the newly established criteria (cytoplasmic intensity ≥1 in ≥50% of tumor cells or any nuclear intensity ≥1) exhibited outstanding detection performance, achieving an overall sensitivity of 94.36% and increasing specificity to 79.89%, compared to 60.22% under the conventional one. Particularly, the detection sensitivity for NTRK3 fusions was significantly enhanced and reached 95.89 %. This study contributes to clarifying NTRK fusion distribution in patients and validates a standardized, sensitive pan-TRK IHC strategy for clinical screening. - Source: PubMed
Publication date: 2026/04/29
Wu ShafeiWang JianYang WentaoHan YuchenZhang ZhihongChen GangMeng BinSun YanLiu YangLi WencaiLi ShengleiWang LifengZhang HongyingGuo LingchuanLiu YuepingLiu XiaodingHong RupingLi KaimiPang JunyiLiang Zhiyong - Virologic profiling is mandatory for the clinical management of Hepatitis-B-surface-Antigen (HBsAg) carriers, positive for antibody against Hepatitis-Delta-Virus (anti-HDV). We analysed the correlations between serum HDV RNA, anti-HDV, HBV-markers and liver disease in a single centre cohort study. - Source: PubMed
Publication date: 2026/05/01
Ricco GabrieleCavallone DanielaColombatto PieroCoco BarbaraOliveri FilippoDamone FrancescoPetralli GiovanniRomagnoli VeronicaSalvati AntonioSurace LidiaCalì AlessiaVianello BarbaraBonino FerruccioBrunetto Maurizia Rossana - Testicular microlithiasis (TM) is common in infertile men, but its management is controversial due to an unclear link to testicular germ cell tumor (TGCT) risk. This scoping review synthesizes evidence to clarify the basis for personalized management of TM, focusing on infertile men. - Source: PubMed
Publication date: 2026/04/15
Zhou JiedongOuyang YongHu ShianXiong YutingLiu Min - Background Type 2 diabetes mellitus (T2DM) is a chronic, non-communicable condition that causes insulin resistance and β-cell malfunction over time. The traditional food scene in India has changed dramatically as a result of rising urbanization and increased consumption of processed, Westernized diets heavy in refined carbs, saturated fats, and added sugars. These dietary changes have greatly contributed to the increased prevalence of type 2 diabetes. Medical nutrition therapy (MNT) is a systematic approach to nutrition management that aims to improve metabolic regulation and treatment results. MNT is often provided by a registered dietitian in collaboration with a diabetologist, and it focuses on personalized, evidence-based dietary guidelines. In this regard, NutroActive Industries Pvt. Ltd., India, has created a diabetic low glycemic load (GL) food product. The product kit contains Diabexy flour, Diabexy sugar substitute drops, Diabexy almond cookies, and Diabexy coconut burfi. These products are intended to provide a structured, low-GL meal plan that may support glycemic management. Although their formulation is nutritionally appropriate, clinical data for its effectiveness and safety are sparse. This randomized pilot trial sought to explore the potential effects of these products in improving glycemic parameters, such as fasting plasma glucose (FPG), postprandial glucose (PPG), and glycated hemoglobin (HbA1c), as well as their tolerance and safety. Method A total of 30 individuals with type 2 diabetes were randomly assigned to control and intervention groups. Baseline characteristics, including age, vital signs, and anthropometric parameters, were comparable between groups (p > 0.03), indicating adequate randomization. Ten participants demonstrated significantly lower postprandial glucose responses to Diabexy atta compared with glucose (iAUC: 52 vs. 241 mmol·min/L), corresponding to a low glycemic index (GI) of 22%. In the intervention group, the low-GL kit was associated with stable HbA1c, changes in fasting insulin that were interpreted alongside HOMA-IR (Homeostatic Model Assessment for Insulin Resistance) to assess insulin dynamics, and improved quality-of-life scores. Safety assessments showed no adverse effects on liver, kidney, or lipid parameters. Indigestion was reported in one participant during the study period; however, it was transient and not considered related to the low-GL intervention kit. Overall, these findings suggest a potential metabolic benefit of Diabexy atta as part of a low-GL dietary approach, within the limitations of this pilot study. Conclusion In this randomized, open-label pilot study, the low-GL dietary intervention was associated with reductions in postprandial glucose levels, stabilization of HbA1c, and improvements in insulin resistance compared with standard care. No clinically significant safety concerns were observed over the study period based on clinical and laboratory assessments. While these findings suggest a potential metabolic benefit of the low-GL approach in individuals with T2DM, they should be interpreted cautiously given the small sample size, short duration, and exploratory nature of the study. Larger, well-controlled trials are warranted to confirm these preliminary observations. - Source: PubMed
Publication date: 2026/03/29
Chahar Ajeet SChauhan NituTiwari PrashantShukla AnupamSharma Pranjal